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Abstract
Anemia during pregnancy is a considerable health problem, with around two-fifths of
pregnant women worldwide being anemic. Many gynecological and infectious diseases
are predisposing factors for anemia during pregnancy. Anemia during pregnancy—
especially the severe form—can lead to various maternal and perinatal adverse effects
such as preterm labor, low birth weight, and intrauterine fetal death. It is one of the
leading causes of maternal mortality. Therefore, preventive measures are needed if
anemia and its adverse effects are to be prevented. Iron and folic acid supplements are
the cornerstone for the prevention of anemia during pregnancy and one of the earliest
preventive measures adopted in antenatal care. Other measures to prevent anemia
during pregnancy include the fortification of principle foods with iron, increasing health
and  nutritional  awareness,  combating  parasitic  infections,  and  improvement  in
sanitation. There is a controversy concerning the benefit of other elements such as zinc,
copper, and magnesium, so the use of these elements is not widely adopted for the
prevention of anemia.
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1. Introduction
Anemia in pregnancy is a major public health problem, where it has been estimated that 41.8%
of pregnant women worldwide are anemic [1]. The majority (at least half) of this burden is
due to iron deficiency [2]. However, there is a significant variation in prevalence of anemia,
both within and between countries.  Because of physiological  changes during pregnancy,
pregnant women are at higher risk of anemia and in particular iron deficiency anemia, which
is  the  most  common  type  of  anemia  during  pregnancy.  Hematological  changes  during
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pregnancy, especially expansion of blood volume, often confuse the diagnosis of anemia and
its treatment. Because of increased iron and folic acid demands during pregnancy, pregnant
women are  more  susceptible  to  develop  anemia.  Moreover,  pregnant  women are  more
susceptible to the other types of anemia that affect other women of childbearing age such as
hereditary  anemia,  sickle  cell  disease  and  aplastic  anemia.  Anemia  during  pregnancy,
particularly the severe form, is associated with increased maternal morbidity and mortality
and contributes to 20% of the maternal mortality in Africa [2–5]. Anemia in pregnancy is
associated with negative consequences for both the woman and neonate. Therefore, great
effort is needed to develop/reassess and implement programs to control and prevent anemia
during pregnancy.
2. Physiological changes during pregnancy related to anemia
During pregnancy, there is a considerable increase in plasma volume, which increases by
40–45% above the level of nonpregnant women. The blood volume expands by 15% com‐
pared with non-pregnancy levels. The disproportionate amount of blood creates the physio‐
logical and dilution anemia during pregnancy [5, 6]. However, these changes are of great
importance and may protect pregnant woman against supine hypotension, guard against
the adverse effects of the expectant blood loss during labor, and meet the demand for in‐
creased blood flow to the uterus and fetus [5, 7–9]. Despite this hemodilution, there is usual‐
ly minimal change in mean corpuscular volume (MCV) or mean corpuscular hemoglobin
(Hb) concentration (MCHC). The increase in iron demand during pregnancy is met by in‐
creased iron absorption. The maternal plasma erythropoietin level increases during preg‐
nancy and reaches its peak in the third trimester [5, 7–9]. This accelerates erythropoiesis, but
hemoglobin concentration and hematocrit decrease.
3. Iron metabolism
In adult men, there is usually little iron loss from the body. Because females lose iron during
menses, their iron needs are greater. Usually only around 4% of the ingested iron is absor‐
bed in the upper part of the small intestine, mainly in the ferrous state, while the majority is
ingested in the ferric state. Many metal-binding proteins bind not only to iron but the other
metals such as zinc and copper. After crossing the intestinal cells, most of the absorbed iron
is bound to apoferritin forming ferritin. Usually around 35% of the transferritin is saturated
with iron. The details of the process, involving intestine, plasma, liver, and bone marrow are
shown in the Figure 1.
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Figure 1. Iron metabolism
4. Iron requirements during pregnancy
The daily requirement of iron is around 1.5 mg in nonpregnant women. This requirement
increases dramatically during pregnancy to reach 6–7 mg/day (total 1000 mg) with ad‐
vanced gestational age. Pregnancy causes a twofold to threefold increase in the requirement
for iron and a 10- to 20-fold increase in folate requirement. The increase in demand for iron is
mainly due to fetal requirement, placenta, blood volume, tissue accretion, and the intra-partum
potential for blood loss [5, 10]. This sixfold increase in need is quite difficult to meet with diet
alone, especially in situations of poverty. In many underdeveloped countries, pregnant woman
may have depleted iron stores and/or iron-deficiency anemia and, therefore, are at increased
risk of becoming anemic during pregnancy and developing the adverse consequences of iron
deficiency and anemia. For this reason iron supplementation during pregnancy is very
important to keep the maternal hemoglobin within the normal range. It was previously
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thought that even in the absence of sufficient iron supplementation, fetal hemoglobin
production was not impaired because the fetus obtains iron even if the mother suffers from
severe anemia. This is now an obsolete theory, and maternal anemia may lead to fetal anemia
and many other perinatal adverse effects.
5. Folate during pregnancy
The normal level of folic acid is not sufficient to prevent megaloblastic changes in bone marrow
in about 25% of pregnant women. Moreover, folic acid deficiency is more likely to occur in
twin pregnancy, and in women taking anti-convulsion and sulfa-containing drugs. All
pregnant women in developing countries should receive daily supplementation of 60 mg iron
and 40 mg folic acid. Folate level is affected by sickle cell disease, malaria, and hemolytic
anemia. The issue of folate deficiency has received global attention due to its association with
neural tube defects.
6. Definition of anemia in pregnancy
The World Health Organization (WHO) defines anemia during pregnancy as a hemoglobin
concentration <11 g/dl. However, this cutoff value for hemoglobin concentration is affected by
many factors such as ethnicity, altitude, and smoking [10]. Anemia in pregnancy is further
classified as mild/moderate (Hb 7–10.9 g/dl) and severe (Hb < 7 g/dl) [2]. The Centers for
Disease Control and Prevention (1990) defined anemia as hemoglobin <11 g/dl in the first and
second trimesters and <10.5 g/dl in the third trimester. This is based on the reduction in
hemoglobin level during pregnancy caused by the disproportion in volume expansion
between the plasma and erythrocytes. This disproportion is considerably greater during the
second trimester. Postpartum anemia is defined by the WHO as hemoglobin <10 g/dl [10].
7. Etiology of anemia
There are several different factors responsible for anemia. The most common is iron deficien‐
cy anemia (IDA), which is generally assumed to represent 50% of cases [11]. Among the various
risk factors for IDA nutritional or low iron intake together with acute blood loss are the leading
causes. During pregnancy, symptoms such as nausea and vomiting together with other
contributing factors may cause maternal anemia; the other factors include history of heavy
menstruation, high parity, short birth spacing, lack of antenatal nutritional education, and
multiple pregnancy. Malabsorption interferes with iron absorption and parasitic infestation
such as hookworm may also lead to low hemoglobin levels. Iron absorption is enhanced by
ascorbic acid and inhibited by phytic acid and tannins present in tea, coffee, and chocolate.
The second common leading cause of anemia in pregnancy is folic acid deficiency. Other
micronutrient deficiency such as vitamin A, B12, and riboflavin, zinc, and copper may also
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contribute to anemia. Malaria, hookworm infestation, infection, and deficiency of a number of
micronutrients are leading causes of anemia during pregnancy. The relative contribution of
each of these factors to anemia during pregnancy varies greatly by geographical location. Iron
deficiency in anemic subjects in poor communities may be complicated by one or more
additional micronutrient deficiencies. The etiologic pattern of anemia during pregnancy is
often complex such that, for example, infection and nutritional deficiencies coexist.
Obstetric/gynecologic
  Previous history of menorrhagia/metrorrhagia
  History of miscarriage
  Fibroid
  Multiple pregnancies
  Teenagers
Infections
  Infections, for example, urinary tract infection
  Parasitic infections, for example
  Malaria, schistosomiasis, and hookworms
  HIV
  Helicobacter pylori
Bleeding from other site
  Peptic ulcer
  Hemorrhoids
General
  Pica, for example, eating mud
  Nutrition habits, for example, vegetarian
Table 1. Causes of and predisposing factors for anemia during pregnancy.
Other etiologies for anemia in pregnancy include malaria, chronic infection including HIV/
AIDS, hemolytic anemia, thalassemia, and sickle cell disease.
Pregnancy is suggested as a possible cause for aplastic anemia due to the suppression of
hematopoiesis by placental lactogens [12]. This is supported by the clinical observation that
pregnancy-associated aplastic anemia is frequently self-limiting, ending with delivery.
Pregnancy is one cause of bone marrow suppression, and aplastic anemia is likely to be
immune-mediated since pregnancy is a state of hypo-immunity, likely involving suppres‐
sion by cytotoxic T lymphocytes. In patients with aplastic anemia, CD4 and HLA-DR+ are
detectable in both blood and bone marrow. The cells produce inhibitory cytokines such as
tumor necrosis factor and gamma interferon, which affect the mitotic cells and induce nitric
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oxide synthase and nitric oxide production by bone marrow cells, related to immune-mediat‐
ed cytotoxicity and elimination of hematopoietic cells.
Table 1. shows causes and predisposing factors for anemia in pregnancy.
8. Diagnosis
While mild anemia is usually asymptomatic and may be detected during routine prenatal
check up for hemoglobin, moderate and severe anemia may present with different symp‐
toms, including fatigue, dizziness, tiredness, lethargy, fainting, palpitation, symptoms of
congestive heart failure, and leg swelling. In severe cases, there may be difficulty in swallow‐
ing and/or blindness if there is a vitamin A deficiency. It is worth mentioning that some of
these symptoms can overlap and hence be attributed to symptoms detected in normal
pregnancy (Table 2).
Fatigue
Dizziness
Tiredness
Lethargy
Fainting
Palpitation
Symptoms of congestive heart failure
Legs swelling
Table 2. Symptoms of anemia during pregnancy.
Pallor and physical findings of iron deficiency may also be present, such as angular stomati‐
tis, smooth tongue, and koilonychias, in the Figure 2.
Figure 2. Signs of IDA (iron deficiency anemia)
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8.1. Signs of IDA
An abdominal examination to rule out enlarged spleen and/or liver is mandatory in approach‐
ing anemic pregnant woman. A complete blood picture (include peripheral blood film) is the
first step in tailoring the next investigations aimed at determining etiology as shown in the
Figure 3.
Figure 3. Peripheral blood picture in IDA
These may include stool examination for hookworms, hemoglobin electrophoresis, and tests
for infectious organisms such as malaria, tuberculosis, and HIV. Bone marrow aspirate or
biopsy may be needed to diagnose the underlying cause of anemia.
The definition and identification of iron deficiency have been problematic, especially in
situations in which chronic inflammation is present. The gold standard for identifying iron
deficiency anemia has been the examination of suitably stained bone marrow aspirates for
storage iron as hemosiderin. Biochemical measurement of iron status is influenced by
inflammation and clearly defined and validated cutoffs for diagnosing iron deficiency in
pregnancy in the presence of coexisting infection have been lacking. A lowered MCV is the
most sensitive indicator of iron deficiency, where serum iron is low and the total binding
capacity raised. Macrocytosis with megaloblastic changes in bone marrow in an indicator of
folate deficiency anemia (Table 3).
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Factor Lower cutoff
Hemoglobin 11 g/dl
Hematocrit 30%
Mean corpuscular volume 80 fl
Mean cell hemoglobin 28 pg
Mean cell hemoglobin concentration 32 g/dl
Serum ferritin 12 μg/l
Total iron binding capacity 15%
Table 3. The lower cut off points of the hematological indices during pregnancy.
9. Consequences of anemia in pregnancy
Anemia during pregnancy is associated with increased maternal morbidity and mortality.
Anemia in pregnancy is associated with negative consequences for both the woman and
neonate. Fetal anemia, low birth weight, preterm birth, and stillbirth have been associated with
anemia [13]. Anemia was observed as a predictor for poor perinatal outcomes such as fetal
anemia and low birth weight deliveries [13, 14]. A meta-analysis showed that anemia during
early pregnancy, but not late pregnancy, is associated with slightly increased risk of preterm
delivery and low birth weight [15]. Interestingly, recent reports revealed that the prevalence
of preeclampsia and eclampsia was significantly higher in women with severe anemia [16]. In
some African countries, anemia was reported to be associated with stillbirth [17, 18]. In
addition, there is also association between anemia and postpartum hemorrhage and pulmo‐
nary edema.
Maternal
Anemic heart failure
Maternal death
Septicemia
Preterm labor
Low tolerance to systemic diseases, for example, heart disease
Postpartum hemorrhage
Lack of tolerance of minimal bleeding
Impaired ability to push during the second stage of labor
Impaired lactation
Breast milk of low nutritional value
Deep venous thrombosis
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Puerperal psychosis
Cognitive abnormalities
Perinatal
Intrauterine growth restriction
Intrauterine fetal death
Low birth weight
Fetal anemia
Low APGAR score
Increased perinatal motility
Increased infant death
Table 4. Complications/adverse effects of anemia during pregnancy.
10. Treatment and prevention
10.1. Dietary advice
As physiological iron requirements are several times higher in pregnancy than they are in the
nonpregnant women, the recommended daily intake of iron for the second half of pregnan‐
cy is 30 mg with iron absorption increasing threefold. The amount of iron absorbed depends
upon the following factors: (1) amount of iron in the diet, (2) its bioavailability, and (3)
physiological requirements. Dietary heme iron is found mainly in red meats, fish, and poultry.
Heme iron absorption is twofold to threefold greater than non-heme iron. Moreover, meat
contains organic compounds (including peptides), which promote the absorption of iron from
other less bioavailable non-heme iron sources. While heme iron is more readily absorbed than
non-heme iron, the latter still forms approximately 95% of dietary iron intake. Ascorbic acid
significantly increases iron absorption from non-heme sources, with the magnitude of this
effect concordant with the increase in quantity of vitamin C in the meal. The bioavailability of
non-heme iron is enhanced by germination and fermentation of cereals and legumes which
results in a decrease in the phytate content, a food constituent that hinders iron absorption.
Tannins in tea and coffee hinder iron absorption on consumption with or shortly after a meal.
Nutritional education is the main objective of antenatal care to assist in the prevention of
anemia. In addition, family planning and control of birth spacing is another preventive
measure that should be considered by health-care providers. The WHO jointly with the
International Nutritional Anemia Consultative Group and the United Nations Children’s Fund
recommend routine supplements of 60 mg iron per day and 400 μg folate per day to all
pregnant women for at least 6 months. This guideline also recommends continuation until 3
months postpartum in areas of high prevalence of anemia (>40%). The standard oral prepara‐
tion, Fefol, comprising 100 mg iron and 350 μg folate, is suitable for both prevention and
treatment. Parenteral iron does not provide rapid correction of hemoglobin levels compared
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with oral form but is an option for those with poor compliance and who cannot tolerate the
oral formulation. It is also suitable in cases of malabsorption. The maximum rise in hemoglo‐
bin achievable with either oral or parenteral formulations is 0.8 g/dl/week. Blood transfusion
is indicated in cases of severe anemia (Hb% < 7 g/dl) and anemia in late pregnancy when
delivery is due.
Referral to secondary care level should be considered if any of the following situations exist:
1. Significant symptoms and/or severe anemia (Hb < 70 g/l), or
2. Advanced gestation (>34 weeks), or
3. If there is no rise in Hb at 2 weeks.
4. In non-anemic women who are at increased risk of iron depletion such as those with:
a. Previous anemia,
b. Multiple pregnancy,
c. Consecutive pregnancies with <1 year’s interval between
d. Vegetarians
e. Women at high risk of bleeding
f. Pregnant teenagers
g. Jehovah’s witnesses.
10.2. Postnatal anemia
The WHO definition for postnatal anemia is Hb < 10 g/dl. Complete blood count should be
checked within 48-hour post-delivery in all women with an estimated blood loss >500 ml and
in women with uncorrected anemia in the prenatal period or symptoms suggestive of
postpartum anemia. Elemental iron 100–200 mg daily for at least 3 months should be offered
to women with Hb < 100 g/l, who are hemodynamically stable, asymptomatic, or have mild
symptoms, and a repeat complete blood count and ferritin level assessment should be
undertaken to ensure hemoglobin and iron stores are replete [17].
10.3. Parenteral iron therapy
Indications for parenteral iron therapy [19]:
1. absolute noncompliance with oral iron therapy
2. intolerance to oral iron therapy
3. proven malabsorption.
Parenteral iron therapy bypasses the natural gastrointestinal regulatory mechanisms to supply
nonprotein-bound iron to the red blood cells. It is characterized by fast increases in Hb and
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better replenishment of iron stores compared with oral therapy, particular iron sucrose.
However, issues concerning its safety are waiting to be addressed.
Contraindications for parenteral iron use are as follows:
1. history of anaphylaxis or reactions to parenteral iron therapy
2. first trimester of pregnancy
3. active acute or chronic infection
4. chronic liver disease.
Appropriate setting and staff trained in management of anaphylaxis should be available on
contemplating usage of parenteral iron.
10.4. Dealing with delivery of women with iron deficiency anemia
With good practice, this situation should generally be avoided; nonetheless, there are instances
when women book late have recently arrived from abroad or have not engaged with antena‐
tal care. In such circumstances, it may be essential to take active measures to minimize blood
loss at parturition. Attention should be paid to delivery in hospital, securing an intravenous
access and blood group and save, and consideration of active management of the third stage
of labor to reduce postpartum blood loss.
10.5. Blood transfusion: indications and risks
There are multiple potential hazards from blood transfusions but most arise from clinical and
laboratory errors. Moreover, specific risks for women of child-bearing age include the potential
for transfusion-induced sensitization to red blood cell antigens, creating a future risk of fetal
hemolytic disease. Massive obstetric hemorrhage is widely appreciated as an important cause
of morbidity and mortality and necessitates prompt use of blood and components as part of
appropriate management.
Both clinical assessment and hemoglobin concentration are of immense significance postpar‐
tum to decide on the optimum method of iron replacement. In the absence of bleeding, the
decision to transfuse blood should be made on an informed individual basis.
Blood transfusion should be reserved for women with:
a. continued bleeding or at risk of further bleeding,
b. imminent cardiac compromise
c. significant symptoms requiring urgent correction.
If, after careful consideration, elective blood transfusion is needed, women should be fully
counseled about potential risks and given written information, and consent should be
obtained.
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10.6. Prophylaxis
Efforts aimed at preventing iron deficiency and iron deficiency anemia among pregnant
women include iron supplementation, fortification of staple foods with iron, increasing health
and nutritional awareness, combating parasitic infections, and improvement in sanitation [20].
A prophylactic dose of 300 μg (0.3 mg) daily during pregnancy was proposed in 1968 by the
WHO.
During pregnancy, women need iron supplementation to ensure they have sufficient iron
stores to prevent iron deficiency [21]. Hence, in most developing countries, iron supple‐
ments are used extensively during pregnancy to prevent and correct iron deficiency and
anemia during gestation.
A dose of 60 mg of elemental iron was accepted as standard supplemental dose in 1959,
depending on estimates of iron needs during pregnancy [22]. This has since been endorsed by
several experts [23, 24]. Gastrointestinal discomfort is a common observation among women
consuming large amounts of supplemental iron, especially if taken on an empty stomach.
Gastrointestinal side effects are recognized as the critical adverse effect on which the tolera‐
ble upper limit of intake for iron is determined. Use of high-dose iron supplements common‐
ly leads to gastrointestinal manifestations, such as constipation nausea, vomiting, and
diarrhea, with the frequency and severity being determined by the amount of elemental iron
released in the stomach.
10.7. Folic acid supplementation
Following publication of a number of studies supporting the periconceptional use of folic acid
in the prevention of neural tube defects, the supplemental dose was increased to 400 μg (0.4
mg) of folic acid daily in 1998. This dose was considered to provide more folic acid than needed
to produce an optimal hemoglobin response in pregnant women. If supplementation is
delayed till after the first trimester of pregnancy, it will not contribute to preventing birth
defects [25]. Interestingly, a recent Cochrane review showed that supplement with folic acid,
alone or in combination with vitamins and minerals, prevents neural tube defects, but it does
not have a clear effect on other birth defects [26].
Likewise, it has been found that folic acid alone, or in combination with vitamin and mineral
supplements during pregnancy, improved iron status in women without affecting perinatal
anemia, perinatal mortality or other infant outcomes [27, 28].
11. Hemoglobinopathies
Hemoglobinopathies such as thalassemias and sickle cell diseases should be considered during
pregnancy because of their impact on maternal and perinatal outcomes. They are genetic
disorders of hemoglobin structure and synthesis and may transmit to the offspring. The main
clinical manifestation of these disorders during pregnancy is anemia. Usually the iron store is
quite normal necessitating folate supplementation without iron to avoid iron overload. Pre-
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conceptual counseling is a very important issue in patients with hemoglobinopathies. It allows
establishment of the hemoglobin status of the parents and prediction of the likelihood of an
affected offspring [29].
11.1. Sickle cell disease
Sickle cell disease is caused by the substitution of glutamic acid by valine at position 6 of the
globin chain. It includes sickle cell anemia, sickle hemoglobin C disease, sickle beta thalasse‐
mias, and sickle cell anemia with alpha thalassemia. Sickling and crystallization of the
hemoglobin are induced by de-oxygenated states such hypoxia, acidosis, and dehydration.
Almost always the patients are already diagnosed prior to pregnancy, but the diagnosis is
made by hemoglobin electrophoresis. Sickle cell disease substantially increases maternal and
perinatal mortality. It leads to miscarriage, intrauterine growth restriction, preterm labor,
preeclampsia, abruptio placentae, and thrombosis [29]. There is also an increased incidence of
infection, and the sickle cell crisis should be managed as aggressively as in nonpregnant
women. The management of sickle cell disease in pregnancy should be in collaboration with
hematologist. Folic acid supplementation with avoidance of iron is very important together
with penicillin prophylaxis. The patient should be removed from factors that may have
triggered the crisis. These may include dehydration in early pregnancy (hyperemesis gravi‐
darum) and during labor. Regular antenatal monitoring, serial growth scans, and intrapar‐
tum avoidance of dehydration, hypoxia, acidosis, and infection are very important, as are
consideration of analgesia and anesthesia. The routine use of prophylactic blood transfusion
is controversial in this situation.
11.2. Thalassemias
The genetically determined hemoglobinopathies termed thalassemias are characterized by
impaired production of one or more of the normal globin peptide chains. Thalassemias occur
according to which globin chain is deficient.
Alpha thalassemia minor (three normal alpha gene) is usually asymptomatic, but the patient
may become anemic. Alpha thalassemia major is incompatible with life, and the fetus is
severely hydropic. Beta thalassemia minor may also be a symptomatic but may present with
iron deficiency anemia with lowered MCV, MCH, and MCHC. The patient will need oral folate
and iron supplementation. Beta thalassemia major in adults presents with iron overload.
12. Acquired hemolytic anemia
This is an uncommon type of anemia and is either primary or secondary. It is usually due to
antibody production. Secondary hemolytic anemia may be due to chronic infection, drugs, or
connective tissue disease. Typically both direct and indirect Coombs tests are positive and
spherocytosis and reticulocytosis are the typical characteristics of a peripheral blood smear.
Steroids are usually effective treatment (prednisolone 1 mg/kg/day). The presentation and
symptoms depend on the severity of hemolysis. Very rarely, as in gestational thrombocyto‐
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penia, there is pregnancy-induced hemolytic anemia. However, usually the condition is benign
and resolves spontaneously. Some obstetric conditions such as pre-eclampsia and eclampsia
may induce micro-angiopathic hemolysis, and this might progressed to hemolysis, elevated
liver enzymes, and low platelets (HELLP) syndrome [29].
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